Cover Image
Read Now

Clinical review report: Netupitant/palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma)

The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemot...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, June 2018
Edition:Version: final
Series:CADTH common drug review
Subjects:
Canada
Nausea / Drug Therapy
Antineoplastic Agents / Adverse Effects
Palonosetron / Therapeutic Use
Antiemetics / Therapeutic Use
Vomiting / Drug Therapy
Pyridines / Therapeutic Use
Nausea / Chemically Induced
Vomiting / Chemically Induced
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC)
Physical Description:1 PDF file (96 pages) illustrations

Similar Items